Report Title:
OpportunityAnalyzer:Uveitis - Opportunity Analysis and Forecasts to 2026 Published On: November 2017
Category: Life Sciences
Pages: 244
Report Overview: OpportunityAnalyzer:Uveitis Opportunity Analysis and Forecasts to 2026 Summary Uveitis is an inflammatory condition of the eye affecting mainly the uvea. It encompasses a heterogeneous collection of disorders characterized by ocular inflammation. Currently, there is only a limited number of approved drugs for the treatment of uveitis. Based on the diverse nature of uveitis , there is a high unmet need for varied therapy approaches. Significant efforts are being made to develop new treatments for uveitis, as current pharmacologic management, which is dominated by competitively priced corticosteroids and also immunosuppressive drugs, is notorious for the development of adverse side effects. GlobalData estimates the drug sales for uveitis in 2016 were approximately $416.5M across the 7MM covered in this report. Over the 10year forecast period, the market is expected to grow to $897.1M at a CAGR of 8.0%. The anticipated introduction of five new drugs will further drive the market by offering novel treatment mechanisms, including new drug delivery routes and novel, noncorticosteroid drug molecules. These new drugs will expand the options available to treat uveitis patients and contribute to overall market growth. Scope Overview of uveitis: including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management. Annualized uveitis market revenue, cost of therapy per patient, and treatment usage patterns in three patient segments including noninfectious mild and moderate anterior uveitis, noninfectious severe anterior uveitis, noninfectious intermediate, posterior and panuveitis, forecast from 2016 to 2026. Key topics covered: strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the uveitis therapeutics market Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for uveitis therapy. The most promising candidate in Phase III and Phase II/III development is profiled. Analysis of the current and future market competition in the global uveitis therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications. Reasons to buy The report will enable you to Develop and design your inlicensing and outlicensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Develop business strategies by understanding the trends shaping and driving the global uveitis therapeutics market. Drive revenues by understanding the key trends, innovative products and technologies, market
24marketreports | International +1 646 781 7170 | www.24marketreports.com
segments, and companies likely to impact the global uveitis therapeutics market in the future. Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors. Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage. Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Table of Contents: 1 Table of Contents 1 Table of Contents 2 1.1 List of Tables 7 1.2 List of Figures 8 2 Executive Summary 9 2.1 Significant Growth Is Expected in the Uveitis Market from 2016 to 2026 9 2.2 R&D and Corporate Strategies Within the Uveitis Market 11 2.3 A LongActing Treatment That Permanently Controls Inflammation, With a Good Short and LongTerm Safety Profile, Remains Elusive 12 2.4 Market Opportunities for New Entrants 13 2.5 LateStage Pipeline Drugs Entering the Uveitis Market Will Be a Key Driver of Growth 14 2.6 What Do Physicians Think? 16 3 Introduction 19 3.1 Catalyst 19 3.2 Related Reports 19 4 Disease Overview 20 4.1 Etiology and Pathophysiology 20 4.1.1 Etiology 21 4.1.2 Pathophysiology 24 4.2 Classification or Staging Systems 26 4.2.1 Uveitis and Systemic Diseases 27 4.3 Symptoms 29 4.4 Prognosis 30 4.5 Quality of Life 31 5 Epidemiology 32 5.1 Disease Background 32 5.2 Risk Factors and Comorbidities 33 5.3 Global and Historical Trends 34 5.3.1 US 36 5.3.2 5EU 37 5.3.3 Japan 38 5.4 Forecast Methodology 39
24marketreports | International +1 646 781 7170 | www.24marketreports.com
5.4.1 Sources 40 5.4.2 Forecast Assumptions and Methods 44 5.5 Epidemiological Forecast for Uveitis 20162026 54 5.5.1 Diagnosed Incident Cases of Uveitis 54 5.5.2 Diagnosed Prevalent Cases of Uveitis 55 5.5.3 AgeSpecific Diagnosed Prevalent Cases of Uveitis 56 5.5.4 SexSpecific Diagnosed Prevalent Cases of Uveitis 57 5.5.5 Diagnosed Prevalent Cases by Anatomical Site of Inflammation 58 5.5.6 Diagnosed Prevalent Cases by Etiology 59 5.6 Discussion 60 5.6.1 Epidemiological Forecast Insight 60 5.6.2 Limitations of the Analysis 60 5.6.3 Strengths of the Analysis 61 6 Current Treatment Options 63 6.1 Overview 63 6.2 Diagnosis and Treatment 63 6.2.1 Diagnosis 63 6.2.2 Treatment Guidelines and Leading Prescribed Drugs 64 6.3 Clinical Practice 66 6.4 Humira Adalimumab 73 6.4.1 Overview 73 6.4.2 Efficacy 78 6.4.3 Safety 79 6.4.4 SWOT Analysis 81 6.5 Retisert Flucinolone Acetonide 81 6.5.1 Overview 81 6.5.2 Efficacy 83 6.5.3 Safety 84 6.5.4 SWOT Analysis 86 6.6 Ozurdex Dexamethasone Acetate 86 6.6.1 Overview 86 6.6.2 Efficacy 89 6.6.3 Safety 90 6.6.4 SWOT Analysis 92 7 Unmet Needs and Opportunity Assessment 93 7.1 Overview 93 7.2 Therapies That Maintain Vision and Control Inflammation 94 7.2.1 Unmet Need 94 7.2.2 Gap Analysis 95 7.2.3 Opportunity 97 7.3 Therapies With Improved Safety Profiles 98 7.3.1 Unmet Need 98 7.3.2 Gap Analysis 99 7.3.3 Opportunity 103 7.4 LongActing and More Efficient Treatment 104 7.4.1 Unmet Need 104
24marketreports | International +1 646 781 7170 | www.24marketreports.com
7.4.2 Gap Analysis 106 7.4.3 Opportunity 109 7.5 Increased Physician Education and Improved Treatment Guidelines 110 7.5.1 Unmet Need 110 7.5.2 Gap Analysis 111 7.5.3 Opportunity 114 7.6 Development of Biomarkers and Different Diagnostic Tests for Various Uveitic Types 115 7.6.1 Unmet Need 115 7.6.2 Gap Analysis 117 7.6.3 Opportunity 117 8 R&D Strategies 118 8.1 Overview 118 8.1.1 Uveitis as an AddOn Indication 118 8.1.2 Uveitis as a First Indication for a New Drug 119 8.1.3 Development of Ophthalmic Routes of Administration 120 8.1.4 Development of Novel Nonsteroid Therapies 120 8.2 Clinical Trials Design 121 8.2.1 Lack of HighQuality Outcome Measures 121 8.2.2 Lack of Consensus on Outcome Measures 123 8.2.3 CorticosteroidSparing Therapy 123 9 Pipeline Assessment 125 9.1 Overview 125 9.2 Opsiria/DE109 Sirolimus 127 9.2.1 Overview 127 9.2.2 Efficacy 131 9.2.3 Safety 133 9.2.4 SWOT Analysis 134 9.3 Durasert Fluocinolone Acetonide 134 9.3.1 Overview 134 9.3.2 Efficacy 140 9.3.3 Safety 141 9.3.4 SWOT Analysis 143 9.4 EGP437 Iontophoretic Dexamethasone Phospaste 144 9.4.1 Overview 144 9.4.2 Efficacy 148 9.4.3 Safety 149 9.4.4 SWOT Analysis 150 9.5 CLSTA Triamcinolone Acetonide 150 9.5.1 Overview 150 9.5.2 Efficacy 156 9.5.3 Safety 157 9.5.4 SWOT Analysis 158 9.6 ADX102 159 9.6.1 Overview 159 9.6.2 Efficacy 162 9.6.3 Safety 163
24marketreports | International +1 646 781 7170 | www.24marketreports.com
9.6.4 SWOT Analysis 164 9.7 Biosimilars Assessment 164 9.8 Amjevita Adalimumab Biosimilar 168 9.8.1 Overview 168 9.8.2 SWOT Analysis 170 9.9 Imraldi Adalimumab Biosimilar 170 9.9.1 Overview 170 9.9.2 SWOT Analysis 172 9.10 Innovative Early Stage Approaches 173 9.10.1 Tesidolumab LFG316 173 9.10.2 Orencia Abatacept 174 9.10.3 Dexamethasone Acetate DexNP 177 9.10.4 LME636 180 9.10.5 Optiquel B27PD 181 9.10.6 Filgotinib 182 9.11 Other Drugs in Development 184 10 Pipeline Valuation Analysis 185 10.1 Clinical Benchmark of Key Pipeline Drugs 185 10.2 Commercial Benchmark of Key Pipeline Drugs 187 10.3 Competitive Assessment 189 10.4 TopLine 10Year Forecast 192 10.4.1 US 196 10.4.2 5EU 199 10.4.3 Japan 203 11 Appendix 206 11.1 Bibliography 206 11.2 Abbreviations 220 11.3 Methodology 224 11.3.1 Forecasting Methodology 224 11.3.2 Diagnosed Prevalent Cases 226 11.3.3 Diagnosed Prevalent Cases by Anatomical Site of Inflammation 226 11.3.4 Diagnosed Cases and DrugTreated Prevalence 226 11.3.5 Disease Severity 227 11.3.6 Drugs Included in Each Therapeutic Class 227 11.3.7 Launch and Patent Expiry Dates 228 11.3.8 General Pricing Assumptions 229 11.3.9 Individual Drug Assumptions 230 11.3.10 Generic Erosion 234 11.3.11 Pricing of Pipeline Agents 235 11.4 Primary Research KOLs Interviewed for This Report 237 11.5 Primary Research Prescriber Survey 239 11.6 About the Authors 240 11.6.1 Analyst 240 11.6.2 Therapy Area Director 240 11.6.3 Epidemiologist 240 11.6.4 Managing Epidemiologist 241
24marketreports | International +1 646 781 7170 | www.24marketreports.com
11.6.5 Global Director of Therapy Analysis and Epidemiology 241 11.6.6 Global Head and EVP of Healthcare Operations and Strategy 242 11.7 About GlobalData 243 11.8 Contact Us 243 11.9 Disclaimer 244
Get More Information about the Report: Report URL: https://www.24marketreports.com/life-sciences/opportunityanalyzeruveitisopportunity-forecast s2026-market-110 To get Report Sample: https://www.24marketreports.com/request-sample/opportunityanalyzeruveitisopportunity-forec asts2026-market-110
24marketreports | International +1 646 781 7170 | www.24marketreports.com